Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved its biosimilar to Amgen’s AMGN blockbuster drug, ...

The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

On March 30, 2026, the FDA approved Ponlimsi, a biosimilar to Prolia, and is reviewing a biosimilar candidate for Xolair.

Amgen has deployed “500 to 1,000” reps in support of Prolia, a biologic osteoporosis treatment that received FDA approval June 1. Sales reps “across [Amgen’s] bone health, inflammation and hospital ...

Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures "The European approval of Prolia is a ...

Nearly two months ahead of schedule, the U.S. Food and Drug Administration has approved Amgen Inc.’s new drug Prolia to treat osteoporosis in postmenopausal women at high risk for fractures, the ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...